<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092793</url>
  </required_header>
  <id_info>
    <org_study_id>Krill-2010</org_study_id>
    <nct_id>NCT01092793</nct_id>
  </id_info>
  <brief_title>Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease</brief_title>
  <official_title>Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerotic coronary heart disease is a condition thought to involve low-grade
      inflammation. Several reports, clinical and epidemiological, have demonstrated that intake of
      fish oil may be beneficial in attenuating the inflammatory process. Still, however, there are
      lacking data in respect to whether differences in composition of various marine oils may
      influence the inflammatory status differently.

      The hypothesis of the current study is that extract from the antarctic krill (Euphausia
      superba) is better than traditional fish oils when compared head-to-head with balanced
      composition of omega 3 content on inflammatory status.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory blood status</measure>
    <time_frame>8 weeks intervention</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment>60</enrollment>
  <condition>Stable Atherosclerotic Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Krill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Krill</intervention_name>
    <arm_group_label>Krill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <arm_group_label>Fish oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-80 years

          -  Sex: Male and female

          -  Stable atherosclerotic coronary heart disease (heart attack &gt;3 months ago or
             objectified angina pectoris).

          -  No hospitalization for heart disease last 3 months.

        Exclusion Criteria:

          -  Unstable heart disease.

          -  Heart failure NYHA class III and IV.

          -  Previous valve and/or aortic surgery

          -  Significant concomitant disease (i.e. diseases with known inflammatory activation -
             e.g. various autoimmune diseases, chronic infections, significant acute infections
             three weeks before or during the study, connective tissue disease, arthritis, chronic
             pulmonary disease or serious liver- or kidney-disease).

          -  Simultaneous involvement in other clinical studies involving intervention.

          -  Planned operation or other invasive procedures (e.g. PCI etc.) during the study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lars Gullestad, Professor, MD, PhD</last_name>
    <phone>+47 23070641</phone>
    <email>Lars.Gullestad@rikshospitalet.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leif Erik Vinge, MD, PhD</last_name>
    <phone>+47 95970301</phone>
    <email>leifvi@klinmed.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Oslo University Hospital / Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Gullestad, Professor, MD, PhD</last_name>
      <phone>+47 23070641</phone>
      <email>Lars.Gullestad@rikshospitalet.no</email>
    </contact>
    <contact_backup>
      <last_name>Leif Erik Vinge, MD, PhD</last_name>
      <phone>+47 95970301</phone>
      <email>leifvie@klinmed.uio.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>March 23, 2010</last_update_submitted>
  <last_update_submitted_qc>March 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lars Gullestad, professor</name_title>
    <organization>Dep. of Cardiology, Oslo University Hospital - Rikshospitalet</organization>
  </responsible_party>
  <keyword>Fish oil</keyword>
  <keyword>Krill</keyword>
  <keyword>CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

